Inactive Instrument

News Tonix Pharmaceuticals Holding Corp Nasdaq

Equities

US8902602015

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Apr. 01	Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
Apr. 01	Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tonix Pharmaceuticals : TNX-102 SL for Fibromyalgia and Long COVID	Apr. 09	PU
Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 01	CI
Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights	Apr. 01	AQ
Tonix Pharmaceuticals Prices $4.4 Million Direct Offering; Revises Existing Warrant Terms -- Shares Tumble	Mar. 28	MT
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering	Mar. 28	AQ
Tonix Pharmaceuticals Gets Rare Pediatric Disease Label For TNX-2900 to Treat Prader-Willi Syndrome	Mar. 25	MT
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome	Mar. 25	AQ
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting	Mar. 21	AQ
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues At the American Chemistry Society Spring 2024 Meeting	Mar. 21	CI
Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya™ for the Management of Fibromyalgia	Mar. 20	AQ
Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024	Mar. 19	AQ
Tonix Pharmaceuticals : TNX-102 SL for Fibromyalgia and Long COVID	Mar. 12	PU
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring	Mar. 12	AQ
Tonix Pharmaceuticals Reports Improvement in ?Brain Fog,? in Fibromyalgia Patients Treated with Tonmya? in Resilient, an Nda-Enabling Phase 3 Clinical Trial	Mar. 11	CI
Tonix Pharmaceuticals Reports Improvement in “Brain Fog,” in Fibromyalgia Patients Treated with Tonmya™ in RESILIENT, an NDA-Enabling Phase 3 Clinical Trial, at the 6th International Congress on Controversies in Fibromyalgia	Mar. 11	AQ
Tonix Pharmaceuticals Selects EVERSANA to Support Launch Strategy and Commercialization Planning of Tonmya for the Management of Fibromyalgia	Mar. 07	AQ
Tonix Pharmaceuticals Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy	Mar. 07	AQ
Tonix Pharmaceuticals Holding Corp. Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy	Mar. 07	CI
Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 Supports Monthly i.v. dosing in Humans	Mar. 06	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Tonix Pharmaceuticals Holding Corp Nasdaq

Equities

US8902602015

Summary

Filters